Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661282 · ClinicalTrials.gov registry record · Phase 1
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02661282: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02661282 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661282, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with glioblastoma. Autologous CMV-specific cytotoxic T cells may stimulate the immune system to attack specific tumor cells and stop them from growing or kill them. Drugs used in chemotherapy, such as temozolomide, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving autologous CMV-specific cytotoxic T cells with temozolomide may be a better treatment for patients with glioblastoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Temozolomide
- PROCEDURE Therapeutic Conventional Surgery
- BIOLOGICAL Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661282
The ClinicalTrials.gov registry entry for NCT02661282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02661282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661282 about?
NCT02661282 is a clinical study titled "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma". This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with glioblastoma. Autologous CMV-specific cytotoxic T cells may stimulate the immune s...
What is the current status of trial NCT02661282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2016-06-01. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT02661282?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temozolomide (DRUG), Therapeutic Conventional Surgery (PROCEDURE), Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02661282?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.